Publication | Closed Access

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Adaptive RadiotherapyRadiation MedicineRadiation TherapyTarget Volume CoverageMedicineRadiopharmaceutical TherapyStereotactic Ablative RadiotherapyRadiation Therapy PlanningSecondary AnalysisOncologyRadiation OncologyTreatment VerificationRadiologyHealth Sciences